Suppr超能文献

不同治疗阶段的患者使用布地奈德/福莫特罗维持和缓解治疗的总体哮喘控制情况。

Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps.

机构信息

Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

出版信息

Respir Res. 2011 Apr 4;12(1):38. doi: 10.1186/1465-9921-12-38.

Abstract

BACKGROUND

Adjusting medication for uncontrolled asthma involves selecting one of several options from the same or a higher treatment step outlined in asthma guidelines. We examined the relative benefit of introducing budesonide/formoterol (BUD/FORM) maintenance and reliever therapy (Symbicort SMART® Turbuhaler®) in patients previously prescribed treatments from Global Initiative for Asthma (GINA) Steps 2, 3 or 4.

METHODS

This is a post hoc analysis of the results of five large clinical trials (>12000 patients) comparing BUD/FORM maintenance and reliever therapy with other treatments categorised by treatment step at study entry. Both current clinical asthma control during the last week of treatment and exacerbations during the study were examined.

RESULTS

At each GINA treatment step, the proportion of patients achieving target levels of current clinical control were similar or higher with BUD/FORM maintenance and reliever therapy compared with the same or a higher fixed maintenance dose of inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) (plus short-acting β2-agonist [SABA] as reliever), and rates of exacerbations were lower at all treatment steps in BUD/FORM maintenance and reliever therapy versus same maintenance dose ICS/LABA (P < 0.01) and at treatment Step 4 versus higher maintenance dose ICS/LABA (P < 0.001). BUD/FORM maintenance and reliever therapy also achieved significantly higher rates of current clinical control and significantly lower exacerbation rates at most treatment steps compared with a higher maintenance dose ICS + SABA (Steps 2-4 for control and Steps 3 and 4 for exacerbations). With all treatments, the proportion of patients achieving current clinical control was lower with increasing treatment steps.

CONCLUSIONS

BUD/FORM maintenance and reliever therapy may be a preferable option for patients on Steps 2 to 4 of asthma guidelines requiring a more effective treatment and, compared with other fixed dose alternatives, is most effective in the higher treatment steps.

摘要

背景

对于未控制的哮喘,调整药物治疗涉及从哮喘指南中概述的相同或更高治疗步骤中选择几种选择之一。我们研究了在先前接受全球哮喘倡议(GINA)第 2、3 或 4 步治疗的患者中引入布地奈德/福莫特罗(BUD/FORM)维持和缓解治疗(Symbicort SMART® Turbuhaler®)的相对益处。

方法

这是五项大型临床试验(>12000 名患者)结果的事后分析,这些临床试验比较了 BUD/FORM 维持和缓解治疗与以研究入组时的治疗步骤分类的其他治疗方法。研究期间,比较了治疗的最后一周的当前临床哮喘控制和发作情况。

结果

在每个 GINA 治疗步骤中,与相同或更高固定剂量吸入皮质激素/长效β2-激动剂(ICS/LABA)(加短效β2-激动剂[SABA]作为缓解剂)相比,接受 BUD/FORM 维持和缓解治疗的患者达到当前临床控制目标水平的比例相似或更高,并且在所有治疗步骤中,BUD/FORM 维持和缓解治疗的发作率均低于同剂量 ICS/LABA(P<0.01),且在治疗第 4 步时低于高剂量 ICS/LABA(P<0.001)。与相同的维持剂量 ICS/LABA(第 2 至 4 步控制和第 3 至 4 步发作)相比,BUD/FORM 维持和缓解治疗在大多数治疗步骤中也实现了更高的当前临床控制率和更低的发作率,与更高的维持剂量 ICS+SABA 相比(第 2 至 4 步用于控制,第 3 和第 4 步用于发作)。对于所有治疗方法,随着治疗步骤的增加,达到当前临床控制的患者比例降低。

结论

对于需要更有效治疗的哮喘指南第 2 至 4 步的患者,BUD/FORM 维持和缓解治疗可能是一种更好的选择,与其他固定剂量替代方案相比,在更高的治疗步骤中最有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afd6/3082240/9709a49fd71b/1465-9921-12-38-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验